Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early morphological response is significantly associated with, but does not accurately predict, relapse in teenagers and young adults aged 10-24 years with acute lymphoblastic leukaemia (ALL): results from UKALL2003.
Furness CL, Kirkwood A, Rowntree C, Vora A, Mitchell C, Samarasinghe S, Goulden N, Moorman A, Hough R. Furness CL, et al. Among authors: goulden n. Br J Haematol. 2019 Feb;184(4):663-666. doi: 10.1111/bjh.15150. Epub 2018 Feb 22. Br J Haematol. 2019. PMID: 29468646 Free article. Clinical Trial. No abstract available.
Activity and toxicity of intramuscular 1000 iu/m2 polyethylene glycol-E. coli L-asparaginase in the UKALL 2003 and UKALL 2011 clinical trials.
Sidhu J, Masurekar AN, Gogoi MP, Fong C, Ioannou T, Lodhi T, Parker C, Liu J, Kirkwood AA, Moorman AV, Das K, Goulden NJ, Vora A, Saha V, Krishnan S. Sidhu J, et al. Among authors: goulden nj. Br J Haematol. 2022 Jul;198(1):142-150. doi: 10.1111/bjh.18158. Epub 2022 Mar 29. Br J Haematol. 2022. PMID: 35348200 Free PMC article. Clinical Trial.
Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C, Moorman AV, Wade R. Vora A, et al. Among authors: goulden n. Lancet Oncol. 2014 Jul;15(8):809-18. doi: 10.1016/S1470-2045(14)70243-8. Epub 2014 Jun 9. Lancet Oncol. 2014. PMID: 24924991 Clinical Trial.
Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion.
Moorman AV, Schwab C, Winterman E, Hancock J, Castleton A, Cummins M, Gibson B, Goulden N, Kearns P, James B, Kirkwood AA, Lancaster D, Madi M, McMillan A, Motwani J, Norton A, O'Marcaigh A, Patrick K, Bhatnagar N, Qureshi A, Richardson D, Stokley S, Taylor G, van Delft FW, Moppett J, Harrison CJ, Samarasinghe S, Vora A. Moorman AV, et al. Among authors: goulden n. Br J Haematol. 2020 Dec;191(5):844-851. doi: 10.1111/bjh.17093. Epub 2020 Sep 14. Br J Haematol. 2020. PMID: 32926422 Free article. Clinical Trial.
134 results